---
document_datetime: 2026-02-19 14:18:37
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/uptravi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: uptravi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.9799648
conversion_datetime: 2026-02-21 12:45:47.308875
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Uptravi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.9 Introduction of, or change(s) to, the | 18/02/2026                          |                                             |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000324283                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.9.b) Implementation of changes which require additional minor assessment (e.g. change to the due date of obligations and conditions of a marketing authorisation and required pharmacovigilance activities in the risk management plan, including changes to the due date of study milestones, and template updates) - Accepted C.9.b - to provide an updated RMP according to the EXPOSURE/EXTRACT Type II variation outcome (EMEA/H/C/003774/II/0045) in which the MAH was requested to remove the now completed EXTRACT study from the additional pharmacovigilance activities. Additionally, the EXPOSURE PASS milestones were updated to align with the current EXPOSURE protocol (Version 8, Amendment   |            |                        |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|
| Variation type IB / EMA/VR/0000322350 | This was an application for a group of variations. B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.2 After first opening (supported by real time data) - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 04/02/2026 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                                          | for sale (supported by real time data) - Accepted                                                                                                                                                                                                                                                                                               |            |                        |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|
| Variation type IB / EMA/VR/0000237755    | B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.z Other variation - Accepted                                                                                                                                                                                                                         | 16/12/2024 | SmPC, Labelling and PL |
| Variation type IB / EMA/VR/0000225754    | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted To extend the due date in the RMP of the EDUCATE study from 2024 to 12 months after PRAC agreement. | 08/11/2024 |                        |
| Variation type IA_IN / EMA/VR/0000234961 | B.II.f.1.a Reduction of the shelf life of the finished product - B.II.f.1.a.2 After first opening - Refused                                                                                                                                                                                                                                     | 05/11/2024 |                        |